% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • usagary1 usagary1 Mar 5, 2013 7:16 AM Flag


    Chris Garabedian, CEO of Sarepta Therapeutics will be presenting "Leveraging a Personalized Medicine Platform to Treat Genetic Sub-Groups " at The World Orphan Drug Congress USA 2013 in Washington D.C. (April 9-11, 2013). In this exclusive conversation with Rare Disease Report, Mr. Garabedian explains why it is a very interesting time to be in the orphan drug business and why he is looking forward to the congress since it highlights how all parties in the rare disease community are working together at a high level of efficiency and integrity.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • #2

      RNA and Oligonucleotide Therapeutics
      April 10 - 13, 2013
      Abstract Deadline: March 1, 2013

      Ryszard Kole, Sarepta Therapeutics
      Adrian Krainer, Cold Spring Harbor Laboratory
      Art Krieg, RaNA Therapeutics
      Bruce Sullenger, Duke University

      We are pleased to announce the third Cold Spring Harbor conference on RNA and Oligonucleotide Therapeutics, which will begin at 7:30 pm on Wednesday April 10 and run through lunch on Saturday, April 13, 2013.

      Keynote Speaker:
      Jeannie Lee, Massachusetts General Hospital

      Topics and Speakers:
      Non-Coding RNAs
      Art Krieg, RaNA Therapeutics

      Modulation of RNA Splicing
      Ryszard Kole, Sarepta Therapeutics
      Giles Campion, Prosensa, The Netherlands
      Stuart Peltz, PTC Therapeutics

      Immunomodulatory Oligos/RNAs
      Sudhir Agrawal, IDERA Pharmaceuticals
      Eli Gilboa, University of Miami

      RNA-mediated Reprogramming
      Victor Dzau, Duke University
      John Cooke, Stanford University

      Larry Gold, SomaLogic, Inc.
      Chris Rusconi, Regado Bioscience

      Delivery of siRNA/Antisense/Antagomirs
      Frank Bennett, Isis Pharmaceuticals
      Laura Sepp-Lorenzino, Merck

      Abstracts are welcomed on all scientific topics related to the development of RNA and other oligonucleotide-based therapeutic approaches. They should contain only new and unpublished material and must be submitted electronically by the abstract deadline. Selection of material for oral and poster presentation will be made by the organizers and individual session chairs. Status (talk/poster) of abstracts will be posted on our web site as soon as decisions have been made by the organizers.

      We are eager to have as many young people as possible to attend since they are likely to benefit most from this meeting. We have applied for funds from industry to partially support graduate students and postdocs.

      We look forward to seeing you at Cold Spring Harbor in April.

24.9252+0.3052(+1.24%)11:57 AMEDT